FDA approves new treatment for Alzheimer's disease
Valerie A. Canady
Abstract
The U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab‐irmb) via its accelerated approval pathway for the treatment of Alzheimer's disease, the agency announced in a news release on Jan. 6. Leqembi is the second of a new category of medications approved for Alzheimer's disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease.
Topics & Concepts
Food and drug administrationDiseaseMedicineAlzheimer's diseaseAgency (philosophy)DrugPharmacologyInternal medicineEpistemologyPhilosophyCholinesterase and Neurodegenerative Diseases